Patent classifications
C07C233/70
NOVEL BENZOIC ACID AMIDE COMPOUND
Disclosed are a novel benzoic acid amide derivative compound, an isomer thereof, a pharmaceutically acceptable salt thereof, a prodrug thereof, a hydrate thereof, or a solvate thereof. The novel compound and the like inhibit melanin production, prevent tyrosinase activity, and have an excellent skin whitening effect.
NOVEL BENZOIC ACID AMIDE COMPOUND
Disclosed are a novel benzoic acid amide derivative compound, an isomer thereof, a pharmaceutically acceptable salt thereof, a prodrug thereof, a hydrate thereof, or a solvate thereof. The novel compound and the like inhibit melanin production, prevent tyrosinase activity, and have an excellent skin whitening effect.
Dual modulator of mGluR5 and 5-HT2A receptor, and use thereof
Disclosed are a dual modulator of mGluR5 and 5-HT2AR (5-HT2A receptor), and use thereof. More specifically, disclosed are a compound which acts as modulator of mGluR5 and an antagonist of 5-HT2AR at the same time, and use thereof as therapeutic agent for pain.
Dual modulator of mGluR5 and 5-HT2A receptor, and use thereof
Disclosed are a dual modulator of mGluR5 and 5-HT2AR (5-HT2A receptor), and use thereof. More specifically, disclosed are a compound which acts as modulator of mGluR5 and an antagonist of 5-HT2AR at the same time, and use thereof as therapeutic agent for pain.
PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING MENTAL DISORDER
Disclosed is a pharmaceutical composition for preventing or treating a mental disorder. More specifically, disclosed is a pharmaceutical composition for treating or preventing a mental disorder, including substance-related and addictive disorder, depressive disorder, anxiety disorder, or post-traumatic stress disorder, by using a compound that simultaneously regulates mGluR5 and 5-HT.sub.2AR.